HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer HOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative
HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D.,
Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500 HOUSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced positive initial
Further Strengthens Senior Executive Leadership Team HOUSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the appointments of John A. Hohneker, M.D., Sigurd C.
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer First patient dosed in registrational Phase 3 trial of AVB-500 in platinum resistant ovarian cancer; on track to conduct interim analysis in first
Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer U.S. FDA Granted Fast Track Designation in 2018 Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the U.S. and Europe in Simplified Adaptive Trial Design Conference Call and Webcast Today at 8:30 a.m.
Initiated a registrational trial of AVB-500 in Platinum Resistant Ovarian Cancer in 1Q 2021 First patient dosed in Phase 1b/2 trial of AVB-500 in Clear Cell Renal Cell Carcinoma in 1Q 2021; On-track to report topline data in 2H 2021 Strengthened balance sheet with $21.0 million registered direct
HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b trial evaluating AVB-500 in platinum resistant ovarian cancer (PROC) will be presented at the 2021
Lead Compound AVB-500 Now Being Evaluated in Broad Range of Cancers HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company has dosed its first patient in an open label Phase
